Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice
Hasan M, Chen J, Matye D, Wang H, Luo W, Gu L, Clayton Y, Du Y, Li T. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice. Journal Of Lipid Research 2023, 64: 100340. PMID: 36737039, PMCID: PMC9986646, DOI: 10.1016/j.jlr.2023.100340.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Acids and SaltsCholestasisFemaleFibroblast Growth FactorsFibrosisHumansLiverMiceMice, Inbred C57BLReceptors, Cytoplasmic and NuclearConceptsBile acid poolKO miceTherapeutic efficacyHepatobiliary injuryBile acid pool sizeBile acid exposureGut barrier integrityGut barrier functionBile acid metabolismAcid poolBile acid synthesisAcid pool sizeBile acid uptakePortal inflammationPortal fibrosisGut exposureDuctular reactionGSK2330672Therapeutic reductionUrsodeoxycholic acidMuricholic acidAcid exposureASBT inhibitorSevere cholangiopathyBarrier integrity